Investment and Growth Strategy
CLINICS & DIAGNOSTICS BUSINESS
OPERATING PERFORMANCE OVERVIEW
REVENUE DEVELOPMENT²
+3.0%
EBITDA¹ DEVELOPMENT
GEORGIA
CAPITAL
☐
CLINICS & DIAGNOSTICS
KEY DRIVERS
Our clinics and diagnostics business's
decreased revenue and EBITDA were due to
the significantly reduced number of COVID
cases in the country and the suspension of
COVID contracts from mid-March 2022 by
the Government.
The business is showing a rebounding trend
in revenues from non-covid services in 1Q23
as evidenced by:
о
О
a 38.5% y-o-y increase in the revenues
from non-COVID, regular ambulatory
services at our polyclinics;
a 103.2% y-o-y increase in revenues from
non-COVID services at our community
clinics;
a 14.5% y-o-y increase revenues from
regular lab tests in 1Q23, at our
diagnostics business.
GEL MILLION
■Clinics
28
-21.7%
-38.9%
21
21
8
4
20
17
4
5
65
15
1Q21
1Q22
1Q23
Diagnostics
- Total
KEY OPERATING HIGHLIGHTS
Clinics
Number of admissions ('000)
Number of registered patients ('000)
638.6
595
Diagnostics
Average revenue per non-covid test (GEL)
Number of non-covid tests performed ('000)
6.1
603
-45.4%
3
3
4
1Q21
1Q22
1Q23
Clinics
Diagnostics
1Q22
VS.
■ 1Q23
Change y-o-y
510.1
617
-20.1%
+3.7%
6.9
+13.4%
608
+0.9%
Georgia Capital PLC | General note: All figures are presented excluding Medical Centre University Clinic (HTMC). 1. Excluding IFRS 16. 2. Total revenue excludes eliminations between the clinics & diagnostics business lines.
72View entire presentation